KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi’s sarcoma

Tao Ma, Harsh Patel, Savalan Babapoor-Farrokhran, Renty Franklin, Gregg L Semenza, Akrit Sodhi, Silvia Montaner

Research output: Contribution to journalArticle

Abstract

Kaposi’s sarcoma (KS) is a vascular neoplasm caused by infection of endothelial or endothelial precursor cells with the Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8). Research efforts have focused on defining the molecular events explaining how KSHV promotes pathological angiogenesis and KS tumor formation. mTOR/HIF-1 is a fundamental pathway driving these processes through the upregulation of angiogenic and inflammatory proteins, including VEGF, ANGPTL4, and ANGPT2. Interestingly, HIF-1 has also been implicated in the upregulation of metabolic genes associated with aerobic glycolysis and the growth of solid tumors. However, whether HIF-1 plays a role in regulating cell metabolism in KS remains unexplored. Here, we show that the HIF-1 metabolic effector, pyruvate kinase 2 (PKM2), is upregulated upon KSHV infection of endothelial cells and is necessary to maintain aerobic glycolysis in infected cells. We further demonstrate that PKM2 regulates KS angiogenic phenotype by acting as a coactivator of HIF-1 and increasing the levels of HIF-1 angiogenic factors, including VEGF. Indeed, inhibition of PKM2 expression blocked endothelial cell migration and differentiation and the angiogenic potential of KSHV-infected cells. We also investigated whether PKM2 regulates the angiogenic dysregulation induced by the KSHV-encoded G protein-coupled receptor (vGPCR), a viral oncogene that promotes Kaposi’s sarcomagenesis through the upregulation of HIF angiogenic factors. Interestingly, we found that PKM2 controls vGPCR-induced VEGF paracrine secretion and vGPCR oncogenesis. Our findings provide a molecular mechanism for how HIF-1 dysregulation fuels both angiogenesis and tumor metabolism in KS and support further investigations on therapeutic approaches targeting HIF-1 and PKM2 for KS treatment.

Original languageEnglish (US)
Pages (from-to)477-488
Number of pages12
JournalAngiogenesis
Volume18
Issue number4
DOIs
StatePublished - Jun 20 2015

Fingerprint

Human Herpesvirus 8
Pyruvate Kinase
Kaposi's Sarcoma
Glycolysis
Vascular Endothelial Growth Factor A
Tumors
Up-Regulation
Angiogenesis Inducing Agents
Endothelial cells
Metabolism
Endothelial Cells
G-Protein-Coupled Receptors
Genes
Angiogenic Proteins
Vascular Neoplasms
Pathologic Neovascularization
Neoplasms
Infection
Oncogenes
Cell Movement

Keywords

  • Angiogenesis
  • Cell metabolism
  • HHV-8
  • Human herpesvirus-8
  • Hypoxia inducible factor-1
  • Kaposi’s sarcoma
  • Kaposi’s sarcoma-associated herpesvirus
  • KSHV
  • Pyruvate kinase 2
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Physiology
  • Clinical Biochemistry

Cite this

KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi’s sarcoma. / Ma, Tao; Patel, Harsh; Babapoor-Farrokhran, Savalan; Franklin, Renty; Semenza, Gregg L; Sodhi, Akrit; Montaner, Silvia.

In: Angiogenesis, Vol. 18, No. 4, 20.06.2015, p. 477-488.

Research output: Contribution to journalArticle

Ma, Tao ; Patel, Harsh ; Babapoor-Farrokhran, Savalan ; Franklin, Renty ; Semenza, Gregg L ; Sodhi, Akrit ; Montaner, Silvia. / KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi’s sarcoma. In: Angiogenesis. 2015 ; Vol. 18, No. 4. pp. 477-488.
@article{3451b5a6389745658fafd43030c40c09,
title = "KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi’s sarcoma",
abstract = "Kaposi’s sarcoma (KS) is a vascular neoplasm caused by infection of endothelial or endothelial precursor cells with the Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8). Research efforts have focused on defining the molecular events explaining how KSHV promotes pathological angiogenesis and KS tumor formation. mTOR/HIF-1 is a fundamental pathway driving these processes through the upregulation of angiogenic and inflammatory proteins, including VEGF, ANGPTL4, and ANGPT2. Interestingly, HIF-1 has also been implicated in the upregulation of metabolic genes associated with aerobic glycolysis and the growth of solid tumors. However, whether HIF-1 plays a role in regulating cell metabolism in KS remains unexplored. Here, we show that the HIF-1 metabolic effector, pyruvate kinase 2 (PKM2), is upregulated upon KSHV infection of endothelial cells and is necessary to maintain aerobic glycolysis in infected cells. We further demonstrate that PKM2 regulates KS angiogenic phenotype by acting as a coactivator of HIF-1 and increasing the levels of HIF-1 angiogenic factors, including VEGF. Indeed, inhibition of PKM2 expression blocked endothelial cell migration and differentiation and the angiogenic potential of KSHV-infected cells. We also investigated whether PKM2 regulates the angiogenic dysregulation induced by the KSHV-encoded G protein-coupled receptor (vGPCR), a viral oncogene that promotes Kaposi’s sarcomagenesis through the upregulation of HIF angiogenic factors. Interestingly, we found that PKM2 controls vGPCR-induced VEGF paracrine secretion and vGPCR oncogenesis. Our findings provide a molecular mechanism for how HIF-1 dysregulation fuels both angiogenesis and tumor metabolism in KS and support further investigations on therapeutic approaches targeting HIF-1 and PKM2 for KS treatment.",
keywords = "Angiogenesis, Cell metabolism, HHV-8, Human herpesvirus-8, Hypoxia inducible factor-1, Kaposi’s sarcoma, Kaposi’s sarcoma-associated herpesvirus, KSHV, Pyruvate kinase 2, VEGF",
author = "Tao Ma and Harsh Patel and Savalan Babapoor-Farrokhran and Renty Franklin and Semenza, {Gregg L} and Akrit Sodhi and Silvia Montaner",
year = "2015",
month = "6",
day = "20",
doi = "10.1007/s10456-015-9475-4",
language = "English (US)",
volume = "18",
pages = "477--488",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi’s sarcoma

AU - Ma, Tao

AU - Patel, Harsh

AU - Babapoor-Farrokhran, Savalan

AU - Franklin, Renty

AU - Semenza, Gregg L

AU - Sodhi, Akrit

AU - Montaner, Silvia

PY - 2015/6/20

Y1 - 2015/6/20

N2 - Kaposi’s sarcoma (KS) is a vascular neoplasm caused by infection of endothelial or endothelial precursor cells with the Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8). Research efforts have focused on defining the molecular events explaining how KSHV promotes pathological angiogenesis and KS tumor formation. mTOR/HIF-1 is a fundamental pathway driving these processes through the upregulation of angiogenic and inflammatory proteins, including VEGF, ANGPTL4, and ANGPT2. Interestingly, HIF-1 has also been implicated in the upregulation of metabolic genes associated with aerobic glycolysis and the growth of solid tumors. However, whether HIF-1 plays a role in regulating cell metabolism in KS remains unexplored. Here, we show that the HIF-1 metabolic effector, pyruvate kinase 2 (PKM2), is upregulated upon KSHV infection of endothelial cells and is necessary to maintain aerobic glycolysis in infected cells. We further demonstrate that PKM2 regulates KS angiogenic phenotype by acting as a coactivator of HIF-1 and increasing the levels of HIF-1 angiogenic factors, including VEGF. Indeed, inhibition of PKM2 expression blocked endothelial cell migration and differentiation and the angiogenic potential of KSHV-infected cells. We also investigated whether PKM2 regulates the angiogenic dysregulation induced by the KSHV-encoded G protein-coupled receptor (vGPCR), a viral oncogene that promotes Kaposi’s sarcomagenesis through the upregulation of HIF angiogenic factors. Interestingly, we found that PKM2 controls vGPCR-induced VEGF paracrine secretion and vGPCR oncogenesis. Our findings provide a molecular mechanism for how HIF-1 dysregulation fuels both angiogenesis and tumor metabolism in KS and support further investigations on therapeutic approaches targeting HIF-1 and PKM2 for KS treatment.

AB - Kaposi’s sarcoma (KS) is a vascular neoplasm caused by infection of endothelial or endothelial precursor cells with the Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8). Research efforts have focused on defining the molecular events explaining how KSHV promotes pathological angiogenesis and KS tumor formation. mTOR/HIF-1 is a fundamental pathway driving these processes through the upregulation of angiogenic and inflammatory proteins, including VEGF, ANGPTL4, and ANGPT2. Interestingly, HIF-1 has also been implicated in the upregulation of metabolic genes associated with aerobic glycolysis and the growth of solid tumors. However, whether HIF-1 plays a role in regulating cell metabolism in KS remains unexplored. Here, we show that the HIF-1 metabolic effector, pyruvate kinase 2 (PKM2), is upregulated upon KSHV infection of endothelial cells and is necessary to maintain aerobic glycolysis in infected cells. We further demonstrate that PKM2 regulates KS angiogenic phenotype by acting as a coactivator of HIF-1 and increasing the levels of HIF-1 angiogenic factors, including VEGF. Indeed, inhibition of PKM2 expression blocked endothelial cell migration and differentiation and the angiogenic potential of KSHV-infected cells. We also investigated whether PKM2 regulates the angiogenic dysregulation induced by the KSHV-encoded G protein-coupled receptor (vGPCR), a viral oncogene that promotes Kaposi’s sarcomagenesis through the upregulation of HIF angiogenic factors. Interestingly, we found that PKM2 controls vGPCR-induced VEGF paracrine secretion and vGPCR oncogenesis. Our findings provide a molecular mechanism for how HIF-1 dysregulation fuels both angiogenesis and tumor metabolism in KS and support further investigations on therapeutic approaches targeting HIF-1 and PKM2 for KS treatment.

KW - Angiogenesis

KW - Cell metabolism

KW - HHV-8

KW - Human herpesvirus-8

KW - Hypoxia inducible factor-1

KW - Kaposi’s sarcoma

KW - Kaposi’s sarcoma-associated herpesvirus

KW - KSHV

KW - Pyruvate kinase 2

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84943348771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943348771&partnerID=8YFLogxK

U2 - 10.1007/s10456-015-9475-4

DO - 10.1007/s10456-015-9475-4

M3 - Article

C2 - 26092770

AN - SCOPUS:84943348771

VL - 18

SP - 477

EP - 488

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 4

ER -